biosurfit achieves IFCC and NGSP certifications for its spinit® HbA1c point-of-care test

 
Lisbon, Portugal, 31st October 2017 biosurfit SA (“biosurfit”), the in vitro point-of-care (PoC) diagnostics company, announces that its spinit® HbA1c point-of-care test has successfully achieved both IFCC (International Federation of Clinical Chemistry and Laboratory Medicine) certification and NGSP (National Glycohemoglobin Standardization Program) certification.
The IFCC maintains the JCTLM (Joint Committee for Traceability in Laboratory Medicine) endorsed […]

By |October 31st, 2017|news|0 Comments

biosurfit and Axonlab Sign Distribution Agreement for Switzerland

 
Axonlab is now a distributor for spinit® in six European countries. biosurfit continues to build a strong commercial presence in more than twenty countries

 
Lisbon, Portugal, 27th June 2017 – biosurfit SA (“biosurfit”), the in vitro point-of-care (PoC) diagnostics company, announces that it has signed a distribution agreement with Axon Lab AG (“Axonlab”) for the commercialisation […]

By |June 27th, 2017|news|0 Comments

biosurfit wins award of distinction “BORN FROM KNOWLEDGE” at the 14th National Meeting of Innovation COTEC-ANI

 
Lisbon, Portugal, 17th May 2017 – biosurfit SA (“biosurfit”), the in vitro point-of-care (PoC) diagnostics company, is pleased to announce the awarded distinction “BORN FROM KNOWLEDGE” at the 14th National Meeting of Innovation COTEC-ANI for the development of the spinit® HbA1c, the POC test to monitor and diagnose diabetes
 
The distinction, first time established, recognizes the […]

By |May 17th, 2017|news|0 Comments

biosurfit announces drawdown of €6 million tranche of funding from the EIB to increase manufacturing capability and support commercialisation of spinit®

Manufacturing scale-up to support rapid commercial roll-out in key markets

 
Lisbon, Portugal, 5th May 2017 – biosurfit SA (“biosurfit”), the in vitro point-of-care (PoC) diagnostics company, announces that it has drawn down the second €6 million tranche from the €12 million loan signed with the European Investment Bank (“EIB”) in November 2015 to fund biosurfit’s transition […]

By |May 5th, 2017|news|0 Comments

biosurfit Achieves Significant Commercial Milestone – 500 spinit® Instruments Placed with European Customers

On track to deliver over 1,000 devices by end of 2017, biosurfit now has a commercial presence in more than twenty countries

Lisbon, Portugal, 3rd April 2017 – biosurfit SA (“biosurfit”), the in vitro point-of-care (PoC) diagnostics company, is pleased to announce that it has reached a significant commercial milestone, and also provides an update on […]

By |April 3rd, 2017|news|0 Comments

biosurfit receives CE Mark for its spinit® HbA1c point-of-care blood test to assist doctors diagnose and monitor diabetes

 

biosurfit receives CE Mark for its spinit® HbA1c point-of-care blood test to assist doctors diagnose and monitor diabetes

spinit® is the only point-of-care instrument able to perform all three of the major blood tests (haematology, immunoassays and clinical chemistry) on the same instrument
spinit® could enable cost-savings due to its three-in-one capabilities
spinit® can assist physicians in diagnosing […]

By |November 30th, 2016|news|0 Comments

biosurfit secures €12 million loan from the European Investment Bank

Biosurfit secures €12 million loan from the European Investment Bank
Supporting the development and commercialization of innovative point-of-care diagnostic tests.
biosurfit SA (“biosurfit” or ”the Company”), the in vitro point-of-care diagnostics company, today announces that it has secured a €12 million loan from The European Investment Bank (“EIB”) to support the funding of the Company’s research, development […]

By |November 27th, 2015|news|0 Comments

biosurfit featured on national news: ” The future today”

Find out the whole story in this link.

(If you don’t understand portuguese, enable english subtitles on the video)

By |November 12th, 2015|news|0 Comments

RevDiagnostics

 

“We are proud to represent spinit ® in the Benelux market and to work with the very driven team of biosurfit. spinit® is a great innovative product with a lot of possibilities in the field of POCT.
The feedback that we have been receiving from customers is tremendously positive. spinit® is already recognized for its […]

By |July 1st, 2015|news|0 Comments

DVU

 

“At DVU we want to be on the top of innovation while providing quality, decentralized and efficient care to our customers. With the implementation of spinit® we are taking one more step forward as a company in that direction.” 

 

Antoon Van Elderen – Chief Business Development at DVU

By |July 1st, 2015|news|0 Comments